ArticleScientific reports2025
Machine learning-guided in Silico identification of Na⁺-NQR inhibitors from Berberis vulgaris and Hydrastis Canadensis phytochemicals against Vibrio cholerae.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating Artificial Intelligence Into Drug Discovery From Medicinal Plants: Current Applications and Infrastructural Challenges.Chemical biology & drug design · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera, a life-threatening diarrheal disease caused by Vibrio cholerae, remains a global health concern. Traditional medicinal plants such as Berberis vulgaris (barberry) and Hydrastis canadensis (goldenseal) have long been used for their antimicrobial properties. This study employed integrated computational approaches to identify potential anti-cholera compounds from these plants by targeting sodium-pumping NADH-ubiquinone oxidoreductase (Na⁺-NQR). Virtual screening identified compounds 122623, 197835, and 638024, along with the control Korormicin, exhibiting favorable binding affinities and hydrogen bonding interactions. Machine learning-based prediction models were further applied to assess functional activity and binding affinity. The study incorporated ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling and density functional theory (DFT) calculations to evaluate physicochemical properties and electronic characteristics of the compounds. Molecular dynamics (MD) simulations demonstrated stable RMSD values for the ligands, with 122623 exhibiting the lowest RMSD (0.3-0.5 nm), closely resembling the control (0.3-0.4 nm), suggesting stable binding. Principal component analysis (PCA) showed tight conformational clusters for complexes with 122623 and 197835, while free energy landscape (FEL) analysis revealed deep energy minima, supporting complex stability. MM/GBSA calculations showed that 122623 had the lowest binding free energy (-38.71 kcal/mol), followed by 638024 (-35.14 kcal/mol) and 197835 (-30.68 kcal/mol). Per-residue energy decomposition identified key residues (Phe137, Val155, Phe159, Phe160) involved in ligand binding. Network pharmacology analysis predicted additional gene targets for the selected compounds, providing insights into their broader therapeutic relevance. Collectively, compounds 122623, 197835, and 638024 derived from Hydrastis canadensis and Berberis vulgaris demonstrated promising inhibitory interactions with the Na⁺-NQR enzyme, suggesting their potential as anti-cholera agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.